Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. This morning, Hamilton, Bermuda based biopharmaceutical comp...
Streetwise Reports | April 1, 2020 |

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. Biopharmaceutical company Chimerix Inc....
Streetwise Reports | April 29, 2020 |

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...
Streetwise Reports | June 18, 2020 |

Buzz on the Bullboards: 2021’s Highlights

2021 was another year of ups, downs, and everything in between, but it was also a year marked by continued global economic uncertainty and a shakeup of some of the hottest investment sectors. I took notice when I realized how often I had been updating my template...
Stockhouse Editorial | December 15, 2021 |

Silver Bullet Creates Credibility

Finding credibility It is very difficult for a new issuer to find goodwill in the capital markets. Historically, and we all have a story to add to this, not every company has told the truth or, in some cases, even known what the truth was, leading to jaded hearts, apathet...
Featured Submission | January 31, 2022 |

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) , a Canada-based clinical stage drug development company that focuses on drug repurposing, believes ...
Streetwise Reports | May 28, 2020 |

It Can Take a Lifetime to Build a Good Company, But Only a Minute to Ruin

(Challenger 350 interior image via Bombardier Inc.) Much like that Will Rogers quote that is all too real, even these days … The world is trying to get as close to a “pre-pandemic” norm as it can and nowhere is this movement more evident than i...
Stockhouse Editorial | July 14, 2021 |

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...
Stockhouse Editorial | December 7, 2021 |

Site Visit Shows Mining Company Now in Development Phase

Project highlights gleaned during the trip are recounted in a BMO Capital Markets report. In a May 21 research note, BMO Capital Markets analyst Andrew Mikitchook reported that during a recent multisite tour, Ivanhoe Mines Ltd.'s (IVN:TSX; IVPAF:OTCQX) "wo...
Streetwise Reports | May 27, 2019 |

Gold Company's 'Ramp-up to Commercial Production on Track for Q2/20'

An update on the project and its production is provided in a Haywood report. In a Jan. 10 research note, Haywood analyst Kerry Smith reported that Lundin Gold Inc. (LUG:TSX) remains on track and on budget to achieve commercial production at its Fruta del Norte proje...
Streetwise Reports | January 22, 2020 |
1 2 3